



## Press release

### Anders Fogstrup becomes new General Manager of STADAPHARM

- Fogstrup joins from Mundipharma and will take over management of the German STADA affiliate focused on Speciality products from September 1, 2020.
- Patrick Schlebrowski will become Global Head Specialties at STADA and will report directly to CEO Peter Goldschmidt.
- Eelco Ockers, EVP Germany: "With his experience and his personality, Anders will make a significant contribution to further strengthening our position in specialty pharmaceuticals."

**Bad Vilbel, August 25, 2020** – Anders Fogstrup will be the new General Manager of STADAPHARM GmbH from September 1, 2020. He joins from Mundipharma and will take over the management of the German STADA subsidiary from Patrick Schlebrowski, who in future, as Global Head Specialities, will control all biosimilar activities on a global level and report directly to STADA CEO Peter Goldschmidt.

Recently, Fogstrup was the managing director of Mundipharma in Germany as well as Northern European countries. In his new role at STADAPHARM he will focus on the expansion of the German biosimilar and specialty business. "With his experience and his personality, Anders will make a significant contribution to further strengthening our position in the Speciality Pharmaceuticals business. Our goal is very clear: We want to fulfill our mission and take care of people's health as a trustworthy partner," emphasizes Eelco Ockers, EVP Germany.

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



Fogstrup is looking forward to the new challenge: "STADAPHARM's potential is enormous - not least thanks to the entrepreneurial spirit and agility that can be felt in every respect at STADA. I am very pleased to now be part of this exciting growth story".

Overall, the native Dane was responsible for the strategic and operative development of Mundipharma for over 13 years in a wide variety of roles and countries and, among other things, built up the German biosimilar business. Fogstrup will report directly to Ockers and be part of his German leadership team.

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

#### ***Additional information for journalists:***

STADA Arzneimittel AG / Media Relations

Stadastrasse 2-18 / 61118 Bad Vilbel / Germany

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215

E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au